Objective： To prove the feasibility and validity of Xing Nao Jing acupoint-injection （XNJ-AI） at Fengchi （GB 20） for pseudobulbar palsy caused by ischemic stroke （PBP-IS）. Methods： An assessor-blinded, two-par...Objective： To prove the feasibility and validity of Xing Nao Jing acupoint-injection （XNJ-AI） at Fengchi （GB 20） for pseudobulbar palsy caused by ischemic stroke （PBP-IS）. Methods： An assessor-blinded, two-parallel-group, randomized controlled trial was conducted, and the patients with PBP-IS were recruited and randomly divided into two groups. Patients in the control group received oral aspirin （100 mg per day for 2 weeks）. In addition to oral aspirin; patients in the treatment group received XNJ-AI at Fengchi （GB 20）, once a day, for two weeks. The primary outcome was assessed by the water-swallowing test （WST）. Thromboxane B2 （TXB2） and 6-keto-prostaglandin F1α （6-keto-PGF1α） in plasma were measured before and after the treatment. Results： In the treatment group, the percentage of swallowing function no less than grade 3 before and after the treatment was 32% and 88%, respectively; in the control group, it was 28% and 76% before and after the treatment, respectively; the difference after the treatment between the two groups was statistically significant （P〈0.05）. There were statistical differences between pre- and post-treatment levels of plasma TXB2 and 6-keto-PGF1α in the two groups （both P〈0.05）. After the treatment, there were significant differences in the levels of plasma TXB2 and 6-keto-PGF1α between the two groups （both P〈0.05）. Conclusion： XNJ-AI at Fengchi （GB 20） can improve the patients＇ swallowing function and balance the levels of TXB2 and 6-keto-PGF1α in plasma.展开更多
基金supported by Chinese Medicine Scientific Research Program of Heilongjiang,No.ZH04B06~~
文摘Objective： To prove the feasibility and validity of Xing Nao Jing acupoint-injection （XNJ-AI） at Fengchi （GB 20） for pseudobulbar palsy caused by ischemic stroke （PBP-IS）. Methods： An assessor-blinded, two-parallel-group, randomized controlled trial was conducted, and the patients with PBP-IS were recruited and randomly divided into two groups. Patients in the control group received oral aspirin （100 mg per day for 2 weeks）. In addition to oral aspirin; patients in the treatment group received XNJ-AI at Fengchi （GB 20）, once a day, for two weeks. The primary outcome was assessed by the water-swallowing test （WST）. Thromboxane B2 （TXB2） and 6-keto-prostaglandin F1α （6-keto-PGF1α） in plasma were measured before and after the treatment. Results： In the treatment group, the percentage of swallowing function no less than grade 3 before and after the treatment was 32% and 88%, respectively; in the control group, it was 28% and 76% before and after the treatment, respectively; the difference after the treatment between the two groups was statistically significant （P〈0.05）. There were statistical differences between pre- and post-treatment levels of plasma TXB2 and 6-keto-PGF1α in the two groups （both P〈0.05）. After the treatment, there were significant differences in the levels of plasma TXB2 and 6-keto-PGF1α between the two groups （both P〈0.05）. Conclusion： XNJ-AI at Fengchi （GB 20） can improve the patients＇ swallowing function and balance the levels of TXB2 and 6-keto-PGF1α in plasma.
